Literature DB >> 10688882

Cyclic peptide formation catalyzed by an antibody ligase.

D B Smithrud1, P A Benkovic, S J Benkovic, V Roberts, J Liu, I Neagu, S Iwama, B W Phillips, A B Smith, R Hirschmann.   

Abstract

Cyclic hexapeptides represent a class of compounds with important, diverse biological activities. We report herein that the antibody 16G3 catalyzes the cyclization of d-Trp-Gly-Pal-Pro-Gly-Phe small middle dotp-nitrophenyl ester (8a) to give c-(d-Trp-Gly-Pal-Pro-Gly-l-Phe) (11a). The antibody does not, however, catalyze either epimerization or hydrolysis. The resulting rate enhancement of the cyclization by 16G3 (22-fold) was sufficient to form the desired product in greater than 90% yield. In absolute rate terms, the turnover of 16G3 is estimated to be 2 min(-1). The background rate of epimerization of 8a was reduced from 10 to 1% and hydrolysis from 50 to 4% in the presence of 16G3. As expected, the catalytic effects of 16G3 were blocked by the addition of an amount of the hapten equal to twice the antibody concentration. We also synthesized three diastereomers of 8a: the d-Trp(1)-d-Phe(6) (8b), l-Trp(1)-l-Phe(6) (8c), and l-Trp(1)-d-Phe(6) (8d) hexapeptides as well as d-Trp'-l-Trp(6) (12) and d-Phe'-l-Phe(6) (13). As expected, the rate enhancement by 16G3 was greatest for 8a, because the stereochemistry of Trp(1) and Phe(6) matches that of the corresponding residues on the hapten used to induce the biosynthesis of 16G3. A model of the variable domain of 16G3 was generated from the primary sequence using the antibody structural database to guide the model construction. The resulting model provided support for some previously proposed interpretations of the kinetic data, while providing valuable new insights for others.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688882      PMCID: PMC15735          DOI: 10.1073/pnas.040534397

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Structural basis for amide hydrolysis catalyzed by the 43C9 antibody.

Authors:  M M Thayer; E H Olender; A S Arvai; C K Koike; I L Canestrelli; J D Stewart; S J Benkovic; E D Getzoff; V A Roberts
Journal:  J Mol Biol       Date:  1999-08-13       Impact factor: 5.469

Review 2.  Catalytic antibodies.

Authors:  S J Benkovic
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

3.  At the crossroads of chemistry and immunology: catalytic antibodies.

Authors:  R A Lerner; S J Benkovic; P G Schultz
Journal:  Science       Date:  1991-05-03       Impact factor: 47.728

4.  Conformations of the third hypervariable region in the VH domain of immunoglobulins.

Authors:  V Morea; A Tramontano; M Rustici; C Chothia; A M Lesk
Journal:  J Mol Biol       Date:  1998-01-16       Impact factor: 5.469

5.  Selective chemical catalysis by an antibody.

Authors:  S J Pollack; J W Jacobs; P G Schultz
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

6.  Canonical structures for the hypervariable regions of immunoglobulins.

Authors:  C Chothia; A M Lesk
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

7.  A super active cyclic hexapeptide analog of somatostatin.

Authors:  D F Veber; R Saperstein; R F Nutt; R M Freidinger; S F Brady; P Curley; D S Perlow; W J Paleveda; C D Colton; A G Zacchei
Journal:  Life Sci       Date:  1984-04-02       Impact factor: 5.037

8.  Peptide synthesis catalyzed by an antibody containing a binding site for variable amino acids.

Authors:  R Hirschmann; A B Smith; C M Taylor; P A Benkovic; S D Taylor; K M Yager; P A Sprengeler; S J Benkovic
Journal:  Science       Date:  1994-07-08       Impact factor: 47.728

9.  Catalytic antibody model and mutagenesis implicate arginine in transition-state stabilization.

Authors:  V A Roberts; J Stewart; S J Benkovic; E D Getzoff
Journal:  J Mol Biol       Date:  1994-01-21       Impact factor: 5.469

10.  Antibody catalysis of peptide bond formation.

Authors:  J R Jacobsen; P G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.